Annovis Bio, Inc. — Director's Dealing 2020

Feb 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Annovis Bio, Inc. (ANVS)
CIK: 0001477845
Period of Report: 2020-01-31

Reporting Person: Whelan, Jr. Robert M. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-31	Common Stock	P	25000	$6.00	Acquired	25000	Direct
2020-01-31	Common Stock	C	59524	—	Acquired	84524	Direct
2020-01-31	Common Stock	C	11176	$4.80	Acquired	95700	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-31	Series A-1 Preferred Stock	$	C	83333	Disposed		Common Stock (59524)	Direct
2020-01-31	Convertible Note	$	C	11176	Disposed		Common Stock (11176)	Direct

Footnotes

F1: The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").

F2: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.

F3: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).